Interim safety and efficacy data to be reported in Q1VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa ...
EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with ...
Theriva Biologics (TOVX) announced the receipt of Scientific Advice from the Committee for Medicinal Products for Human Use ...
Tea may offer powerful health benefits, but how it is prepared and consumed matters. Tea has a long history as both a ...
Turkey: A pilot study published in BMC Ophthalmology suggests that a gamified, app-based multimodal visual therapy may offer ...
Time-restricted eating has been widely promoted as a simple way to boost metabolic health, but new research paints a more complicated picture. When calorie intake stayed the same, an eight-hour eating ...
MedPage Today on MSN
Overcoming CDK4/6 Inhibitor Resistance in HR-Positive/HER2-Negative Breast Cancer
In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...
South Korea: In a post hoc analysis of the randomized PULSAR trial, aflibercept 8 mg demonstrated noninferior visual outcomes ...
The researchers also examined potential health risks linked to cannabis use. Long-term data from adolescents suggested that ...
Did you miss the most popular gastroenterology stories this year? Medscape Medical News tracked the news most popular with ...
HHS Secretary Robert F. Kennedy Jr.s CDC just funneled a $1.6 million dollar grant to researchers to carry out an unethical and scientifically unjustified randomized clinical trial of the birth dose o ...
Rezolute, Inc. is downgraded to a Sell after its phase 3 sunRIZE trial for congenital hyperinsulinism failed. Learn more about RZLT stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback